Clinical Trial Update: Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of the long-acting GLP-1 analogue NNC0113-0987 in health…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• NNC0113-0987

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED